Dr. Kandan Kulandaivel, MD

Dr. Kulandaivel practices at Abington Neurological Associates Ltd in Willow Grove, Pennsylvania.

Dr. Kulandaivel's NPI, 1104089119, was assigned on July 9, 2008. Dr. Kulandaivel holds Pennsylvania license MD436179.

Dr. Kulandaivel's primary practice is Abington Neurological Associates Ltd, at 2325 Maryland Rd, Willow Grove, PA 19090 in Montgomery County. The practice phone is (215) 957-9250.

Dr. Kulandaivel's primary practice is Abington Neurological Associates Ltd in Willow Grove, Pennsylvania. Dr. Kulandaivel is also affiliated with Jefferson Einstein Philadelphia Hospital. The medical group on file is Jefferson Abington Hospital. Dmand AI also links Dr. Kulandaivel to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kulandaivel practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kulandaivel's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kulandaivel is licensed in Pennsylvania.

CMS data shows 1,048 Medicare services from Dr. Kulandaivel across 14 procedure codes in 2024, for 529 Medicare patients. Medicare paid $103,475 for them.

CMS counts 529 Medicare patients who saw Dr. Kulandaivel in 2024. The largest group is 75 to 84, with 214 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 1.90, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kulandaivel's median patient age at 72, with 58% women.

In 2024, Dr. Kulandaivel wrote 536 Medicare Part D claims for 157 patients. 88% of them were for generic drugs. CMS names the drug for 387 of them, across 13 drugs with 11 or more claims each, at $172,976 in total drug cost. In 2023, CMS named 503 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Kulandaivel for performance year 2024, reported as part of a group. Dr. Kulandaivel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kulandaivel as offering telehealth.

Dmand AI links 5 papers to Dr. Kulandaivel, published from 2011 to 2015. 2011 was the busiest year, with 3. The most frequent topics are Electroencephalography, Brain Waves and Seizures. Dr. Kulandaivel's most frequent co-authors are Kajalben Buddhdev, MD, Matthew Robert Burns, MD, PhD and Karen Carvalho, MD.

CMS Open Payments shows 570 general payments to Dr. Kulandaivel from 66 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 64% of the total. Bristol-Myers Squibb Company paid the most, $3,768.